Epirus may raise $30 million through at-the-market offering of shares

Agent BTIG will conduct the offering and will be paid a 3% commission

By Devika Patel

Knoxville, Tenn., March 1 – Epirus Biopharmaceuticals Inc. negotiated a $30 million at-the-market equity sales agreement with BTIG, LLC on Feb. 29, according to a prospectus supplement and 8-K filed Tuesday with the Securities and Exchange Commission.

BTIG will be paid a 3% commission.

Proceeds will be used for general corporate purposes, which may include research and development, clinical trials, commercialization activities and working capital.

The biopharmaceutical company is based in Boston.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.